3 March 2026 - BEAM ALLIANCEBEAM is turning 10!What a journey since the association was founded in 2016! Since then, awareness of the looming AMR problem has grown,…
11 December 2025 - BEAM ALLIANCEEU Reaches Landmark Agreement on Pharmaceutical Legislation RevisionAfter a long night of negotiations, EU co-legislators have reached a long-awaited political agreement on the revision of the Union’s…
20 October 2025 - BEAM ALLIANCEDefining Eligibility for ‘Priority Antimicrobials’: A Critical Step for Effective PULL IncentivesThe General Pharmaceutical Legislation (GPL) should provide broad guidelines for eligibility, leaving the EMA to refine the details. The GPL…
20 October 2025 - BEAM ALLIANCETransferable Priority Review Vouchers (TPRVs): Lessons from the US, Implications for EUIf a choice must be made, TEEV offer a clearer, more reliable incentive for SMEs, making them a more appealing…
20 October 2025 - BEAM ALLIANCEThe Future of the TEE Voucher in EU Pharmaceutical LegislationThe TEE Voucher is widely supported by SMEs, industry, and investors. Though not perfect, its predictability makes it attractive to…
20 October 2025 - BEAM ALLIANCEHow Can a Subscription Model Help Incentivizing Antimicrobial Innovation in the EU?An EU-funded revenue guarantee (ensuring predictability and reducing reliance on voluntary participation) could be highly effective, provided the incentives are…
16 April 2026 - BioVersysBioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100Achieving first patient first visit in the RIV-TARGET trial marks a significant milestone for BioVersys in the development of BV100…
15 April 2026 - BioVersysBioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026To effectively combat antimicrobial resistance, global cross-industry collaboration is of paramount importance. Clinicians, academic researchers, public-private partners, policy makers, and…
13 April 2026 - BioVersysData published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)The data provide a compelling scientific foundation in understanding the potential positioning of AlpE in future drug regimens to treat…
9 April 2026 - Basilea Pharmaceutica InternationalBasilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420BAL2420 offers a new mode of action with the potential to address significant unmet medical needs in the treatment of…
31 March 2026 - BioVersysBioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian HealthEarly-stage partnerships with leading institutes and health centers from around the world grants us access to the best science to…
23 March 2026 - ANTABIOAntabio and GARDP join forces to identify potential next-generation antibioticsDrug-resistant infections are rising at an alarming pace, leaving patients worldwide with too few effective treatment options,” said Marc Lemonnier,…
22 September 2026GAMRIC – Global AMR Innovators ConferenceThe Global AMR Innovators Conference (GAMRIC) is an event that brings together researchers, academics, and industry professionals from around the…
25 June 2026Therapeutics and Antimicrobial Resistance (AMR)The meeting aims to strengthen cross-disciplinary connections, highlight opportunities for impact, and catalyse new initiatives in therapeutics research, outreach and…
28 April 2026REVIVE Webinar: Natural product-inspired antibiotics: Successes and future prospectsThis webinar will explore the successes of natural product-inspired antibiotics and examine their continued potential for the discovery and development…
17 April 2026ESCMID Global 2026ESCMID Global is the world’s premier meeting in the fields of Clinical Microbiology and Infectious Diseases.
26 March 2026REVIVE Webinar: Journal Club: Key findings from recent publications in antimicrobial R&DIn this webinar, individuals who have co-authored publications that have had particular impact in the field of antimicrobial R&D will…
13 March 2026REVIVE Webinar: Current developments in Clostridioides difficile prevention, therapy and R&DREVIVE webinar being done in collaboration with the Peggy Lillis Foundation